Open AccessP840: A MATCHING‐ADJUSTED INDIRECT COMPARISON OF THE EFFICACY OF PEGCETACOPLAN USING PRINCE TRIAL DATA VERSUS RAVULIZUMAB AND ECULIZUMAB IN COMPLEMENT‐NAÏVE PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA
Author(s) -
Wong R.,
Fishman J.,
Wilson K.,
Yeh M.,
Hakimi Z.,
Yee C.,
Huynh L.,
Duh M. S.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000846244.47350.40
Subject(s) - paroxysmal nocturnal hemoglobinuria , medicine , eculizumab , hemoglobinuria , peg ratio , clinical trial , randomized controlled trial , hemolysis , gastroenterology , immunology , complement system , antibody , finance , economics